Efficacy of nintedanib on severe COVID-19 pneumonia.

Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019: Historical control study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051200036

Enrollment

Registered

2020-07-27

Start date

2020-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pneumonia induced by COVID-19 COVID-19

Interventions

Administration of nintedanib via nasogastric tube

nintedanib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Obtaining sufficient informed consent for this trials from participates or their close relatives 2) 20 years or older at the time of informed consent 3) Confirmed COVID-19 by PCR assay or LAMP assay 4) Respiratory failure requiring mechanical ventilation 5) Availability of a nasogastric tube

Exclusion criteria

Exclusion criteria: 1) History of Idiopathic pulmonary fibrosis 2) History of chronic liver failure (Child Pugh B or C) 3) Breastfeeding and pregnancy 4) History or proven risk factors of thrombosis 5) Proven risk factors of bleeding 6) Unavailable to use enteral tube 7) Ineligibility for other reasons

Design outcomes

Primary

Measure	Time frame
28 days mortality after the initiation of mechanical ventilation	—

Secondary

Measure	Time frame
1) Gastrointestinal adverse events within 28 days after adiministration of nintedanib 2) Liver failure within 28 days after adiministration of nintedanib 3) P/F ratio and KL-6, 14 days and 28 days after the initiation of mechanical ventilation	—

Contacts

Public ContactYutaka Umemura

Osaka

plum0022@yahoo.co.jp+81-6-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026